Literature DB >> 26202271

Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics.

Ping Zhang1, Lidija Covic, Athan Kuliopulos.   

Abstract

Lipopeptides based on the intracellular loops of cell-surface receptors, known as "Pepducins," represent a promising new class of compounds used for the study of membrane proteins and as potential therapeutics in a variety of diseases. Detailed knowledge of the three-dimensional structure of G-protein-coupled receptors (GPCRs) and delineation of the mechanisms of pepducin activation and biased G-protein signaling has facilitated the development of even more potent pepducin allosteric modulators.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202271      PMCID: PMC4838413          DOI: 10.1007/978-1-4939-2806-4_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  62 in total

1.  Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.

Authors:  L Covic; A L Gresser; A Kuliopulos
Journal:  Biochemistry       Date:  2000-05-09       Impact factor: 3.162

2.  Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer.

Authors:  Jaroslaw Cisowski; Katie O'Callaghan; Athan Kuliopulos; John Yang; Nga Nguyen; Qing Deng; Eric Yang; Michael Fogel; Sarah Tressel; Caitlin Foley; Anika Agarwal; Stephen W Hunt; Tom McMurry; Larry Brinckerhoff; Lidija Covic
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

3.  Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells.

Authors:  L Kamath; A Meydani; F Foss; A Kuliopulos
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.

Authors:  Lidija Covic; Christopher Singh; Hedy Smith; Athan Kuliopulos
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

5.  Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.

Authors:  Carey Kimmelstiel; Ping Zhang; Navin K Kapur; Andrew Weintraub; Barath Krishnamurthy; Vilma Castaneda; Lidija Covic; Athan Kuliopulos
Journal:  Circ Cardiovasc Interv       Date:  2011-03-01       Impact factor: 6.546

6.  Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells.

Authors:  Boris Tchernychev; Yong Ren; Pallavi Sachdev; Jay M Janz; Lynn Haggis; Adam O'Shea; Ed McBride; Richard Looby; Qing Deng; Thomas McMurry; Manija A Kazmi; Thomas P Sakmar; Stephen Hunt; Kenneth E Carlson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-07       Impact factor: 11.205

7.  The structural basis of agonist-induced activation in constitutively active rhodopsin.

Authors:  Jörg Standfuss; Patricia C Edwards; Aaron D'Antona; Maikel Fransen; Guifu Xie; Daniel D Oprian; Gebhard F X Schertler
Journal:  Nature       Date:  2011-03-09       Impact factor: 49.962

8.  Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity.

Authors:  Pierluigi Valente; Asia Fernández-Carvajal; María Camprubí-Robles; Ana Gomis; Susana Quirce; Félix Viana; Gregorio Fernández-Ballester; José M González-Ros; Carlos Belmonte; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  FASEB J       Date:  2011-02-09       Impact factor: 5.191

9.  Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.

Authors:  Søren G F Rasmussen; Hee-Jung Choi; Juan Jose Fung; Els Pardon; Paola Casarosa; Pil Seok Chae; Brian T Devree; Daniel M Rosenbaum; Foon Sun Thian; Tong Sun Kobilka; Andreas Schnapp; Ingo Konetzki; Roger K Sunahara; Samuel H Gellman; Alexander Pautsch; Jan Steyaert; William I Weis; Brian K Kobilka
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

10.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.

Authors:  Lidija Covic; Meghna Misra; Jehangir Badar; Christopher Singh; Athan Kuliopulos
Journal:  Nat Med       Date:  2002-09-23       Impact factor: 53.440

View more
  8 in total

Review 1.  Extramembranous Regions in G Protein-Coupled Receptors: Cinderella in Receptor Biology?

Authors:  Sreetama Pal; Amitabha Chattopadhyay
Journal:  J Membr Biol       Date:  2019-08-30       Impact factor: 1.843

Review 2.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

3.  The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.

Authors:  André Holdfeldt; Sarah Line Skovbakke; Malene Winther; Michael Gabl; Christina Nielsen; Iris Perez-Gassol; Camilla Josephine Larsen; Ji Ming Wang; Anna Karlsson; Claes Dahlgren; Huamei Forsman; Henrik Franzyk
Journal:  J Biol Chem       Date:  2016-07-15       Impact factor: 5.157

Review 4.  Designer Approaches for G Protein-Coupled Receptor Modulation for Cardiovascular Disease.

Authors:  Laurel A Grisanti; Sarah M Schumacher; Douglas G Tilley; Walter J Koch
Journal:  JACC Basic Transl Sci       Date:  2018-08-28

Review 5.  Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.

Authors:  Lidija Covic; Athan Kuliopulos
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

Review 6.  Probing GPCR Dimerization Using Peptides.

Authors:  Zara Farooq; Lesley A Howell; Peter J McCormick
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling.

Authors:  Laurel A Grisanti; Toby P Thomas; Rhonda L Carter; Claudio de Lucia; Erhe Gao; Walter J Koch; Jeffrey L Benovic; Douglas G Tilley
Journal:  Theranostics       Date:  2018-09-09       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.